Prostate Cancer VA Rating

Overview

Active malignancy (during treatment plus 6 months after) = 100%.

After the 6-month mandatory examination, VA rates the residuals — typically urinary incontinence and/or erectile dysfunction.

Agent Orange and PACT Act both list prostate cancer as a presumptive condition.

In Depth

Prostate cancer is an Agent Orange presumptive under 38 CFR § 3.309(e) and is among the malignancies most frequently appealed after treatment, because the residuals evaluation so often understates what the veteran actually lives with.

The malignancy itself is evaluated under 38 CFR § 4.115b, Diagnostic Code 7528. Malignancies rated at 100 percent under 38 CFR Part 4 carry a note directing that the total evaluation continues during active disease and for six months following the cessation of surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure. VA must then schedule a mandatory examination, and any reduction from the 100 percent evaluation is made under the procedures in 38 CFR § 3.105(e) — advance written notice, at least 60 days to submit evidence, and 30 days to request a predetermination hearing. If the mandatory exam did not happen, or the notice period was not honored, that is a procedural issue separate from the medical question of how bad the residuals are.

After the convalescent period, DC 7528 directs that the disability be evaluated on residuals as voiding dysfunction or renal dysfunction, whichever is predominant. Voiding dysfunction under 38 CFR § 4.115a is rated on the objective facts of urine leakage — specifically the frequency of absorbent material changes per day — or on urinary frequency, or obstructed voiding. The number of pads per day is not a detail; it is the rating criterion.

Erectile dysfunction after prostatectomy or radiation is a separate matter. Where there is loss of use of a creative organ, special monthly compensation under 38 CFR § 3.350(a) is payable in addition to the schedular evaluation, and it is frequently missed in decisions where nobody claimed it.

Recurrence signaled by a rising PSA and the start of salvage radiation or androgen deprivation therapy can restart the active-disease analysis. The oncology record showing the recurrence date and the therapy start date is the evidence that matters.

How to Establish Service Connection

• Agent Orange / herbicide presumption (Vietnam, Korean DMZ, qualifying locations).
• PACT Act presumption for additional exposure locations.

Rating Criteria

Paraphrased from 38 CFR § 4.115b, Diagnostic Code 7528

See what each percentage pays in 2026 and how it combines with your current rating →

Evidence Checklist

• Pathology report confirming diagnosis.
• Treatment records (surgery, radiation, hormone therapy).
• Exposure documentation (DD-214, deck logs, AO/PACT presumptive locations).

Evidence VA Commonly Cites in These Claims

Descriptive summary of evidence types frequently referenced in rating decisions for this condition. Not a checklist of actions to take — every claim is decided on its own facts.

• ★Get the pathology report and the oncology treatment summary into the file — the dates therapy started and stopped are what set the six-month convalescent window.
• ★List every residual separately when the issue is evaluated after treatment; residuals that are never identified are generally never rated.
• ★Ask the treating oncologist to document ongoing surveillance, maintenance therapy, or hormone therapy where it applies — continuing therapy can be relevant to whether the active-disease evaluation should have continued.
• ★For presumptive exposure, put the service documentation in the file: DD-214, unit assignments, deployment orders, or the location and date range establishing covered service.
• ★Where a reduction from 100 percent is proposed, respond within the 60-day evidence window and request the predetermination hearing within 30 days if you want one — those windows are separate.
• ★Keep a dated log of absorbent material changes per day — that number maps directly onto the voiding dysfunction criteria.
• ★Claim erectile dysfunction and ask that special monthly compensation for loss of use of a creative organ be considered under 38 CFR § 3.350(a).
• ★If PSA has risen and salvage therapy started, get those dates documented; recurrence is not a new claim, it is a change in disease status on a service-connected condition.

Illustrative Scenarios

These are hypothetical educational examples — not actual case results, predictions, or guarantees of outcomes.

Common pitfalls VA sees

• Assuming the 100 percent evaluation continues indefinitely. It does not; the schedule contemplates reevaluation six months after therapy ends.
• Letting the mandatory post-treatment examination pass without documenting residuals, then disagreeing only after the reduction takes effect.
• Claiming only the cancer and never claiming the neuropathy, scars, fatigue, endocrine, or mental health residuals it produced.
• Missing the 60-day evidence window in a proposed-reduction letter because it looks like a form letter rather than a deadline.
• Not reporting pad use at the examination out of embarrassment, when pad changes per day are the literal rating criterion.
• Never raising special monthly compensation for loss of use of a creative organ after prostatectomy or radiation.

Common Secondary Conditions

Conditions frequently service-connected as secondary to Prostate Cancer:

What the C&P Exam Documents

General information about how this condition is typically evaluated. This is not coaching on what to say and is not a substitute for medical or legal advice.

• →Bring the pad log; report the daily number, not a range.
• →Report nighttime voiding frequency as a count, not as 'often.'
• →Raise erectile dysfunction explicitly, including whether medication or a device is used and whether it works.
• →Mention any recurrence, rising PSA, or current androgen deprivation therapy.

Frequently Asked Questions